title: Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment.
abstract: OBJECTIVE
  Prednisone is frequently used in the treatment of elderly-onset rheumatoid arthritis (RA), but the balance between efficacy and toxicity, including the effect on bone mass, has not been investigated in long-term studies. This prospective, randomized study was undertaken to compare disease activity and bone mass during long-term treatment with prednisone versus chloroquine in this patient population.
  
  
  METHODS
  Patients with active RA diagnosed at age > or = 60 were randomized to receive prednisone (15 mg/day for 1 month, with the dosage tapered as low as possible thereafter) (n = 28) or chloroquine (n = 28). Patients who did not show a response received other second-line drugs as an adjunct to prednisone or as a replacement for chloroquine. Bone mass was measured by dual-energy x-ray absorptiometry. The study duration was 2 years.
  
  
  RESULTS
  During the 2 years, treatment with other second-line drugs was needed for 12 patients in the prednisone group (43%) and 8 in the chloroquine group (29%). Functional capacity and disease activity improved significantly in both groups and did not differ significantly between the groups, except for a greater improvement in the prednisone group at 1 month. Radiographic scores for joint destruction progressed similarly in both groups. There was a nonsignificant excess bone loss of 1.8% in the spine and 1.5% in the hip in the prednisone group, compared with the chloroquine group.
  
  
  CONCLUSIONS
  Neither treatment was entirely satisfactory since a significant number of patients needed an additional second-line drug over the 2-year period.
authors.affiliation: Department of Rheumatology, University Hospital, Leiden, The Netherlands.
authors.forename: D
authors.initials: D
authors.lastname: van Schaardenburg
authors.forename: R
authors.initials: R
authors.lastname: Valkema
authors.forename: B A
authors.initials: BA
authors.lastname: Dijkmans
authors.forename: S
authors.initials: S
authors.lastname: Papapoulos
authors.forename: A H
authors.initials: AH
authors.lastname: Zwinderman
authors.forename: K H
authors.initials: KH
authors.lastname: Han
authors.forename: E K
authors.initials: EK
authors.lastname: Pauwels
authors.forename: F C
authors.initials: FC
authors.lastname: Breedveld
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects*; D016723:Bone Remodeling / Q000187:drug effects; D002738:Chloroquine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000209:etiology; D006620:Hip Fractures / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011859:Radiography; D013904:Thoracic Vertebrae / Q000293:injuries; D016896:Treatment Outcome; D000092464:Elbow Injuries
chemical_list: D002738:Chloroquine; D011241:Prednisone